LAVA THERAPEUTICS N.V.
3.90%
1,014,751
1840748
N51517105
Oct 19, 2025
Oct 22, 2025, 04:32 PM
Reporting Persons (5)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Cooperatieve Gilde Healthcare IV U.A. | Other | 3.90% | 1,014,751 | 0 | 1,014,751 |
| Gilde Healthcare IV Management B.V. | Other | 3.90% | 1,014,751 | 0 | 1,014,751 |
| Gilde Healthcare Holding B.V. | Other | 3.90% | 1,014,751 | 0 | 1,014,751 |
| Manapouri B.V. | Other | 3.90% | 1,014,751 | 0 | 1,014,751 |
| Martemanshurk B.V. | Other | 3.90% | 1,014,751 | 0 | 1,014,751 |
Disclosure Items (3)
Common shares, Euro 0.12 nominal value per share
LAVA THERAPEUTICS N.V.
Yalelaan 62, Utrecht, P7, 3584 CM
According to the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on August 13, 2025, there were 26,305,295 Common Shares outstanding as of August 8, 2025. Gilde Healthcare is the record holder of an aggregate of 1,014,751 Common Shares, which represents beneficial ownership of approximately 3.9% of the outstanding Common Shares as of August 8, 2025. GHCIVM, as the manager of Gilde Healthcare, has the power to vote and dispose of securities held by Gilde Healthcare and may be deemed to beneficially own the securities held of record by Gilde Healthcare. As a result, each of the Reporting Persons may beneficially own 1,014,751 Common Shares, or approximately 3.9% of the outstanding Common Shares.
Each Reporting Person has shared power to vote and dispose of 1,014,751 Common Shares.
On October 20, 2025, Gilde Healthcare sold 1,000,000 Common Shares at a weighted average price per share of $1.4647 for aggregate proceeds of approximately $1,464,700.00. On October 21, 2025, Gilde Healthcare sold 933,030 Common Shares at a weighted average price per share of $1.4664 for aggregate proceeds of approximately $1,368,195.19.
As of October 21, 2025, the Reporting Persons ceased to beneficially own more than 5% of the Issuer's outstanding Common Shares.